A Cochrane meta-analysis that compared ACE inhibitors with ARBs in primary hypertension recommended ACE inhibitors as the preferred RAAS inhibitor and stated, “while ARBs are slightly better tolerated than ACE inhibitors, there is a higher quality of data supporting the use of ACE inhibitors to prevent death, strokes, and heart disease that must be considered before choosing ARB over ACE inhibitors” [25]. This evidence concerns the gene ACE and heart disorder.